Scissortail Wealth Management LLC boosted its stake in shares of Nutex Health Inc. (NASDAQ:NUTX - Free Report) by 485,900.0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,720 shares of the company's stock after purchasing an additional 9,718 shares during the quarter. Scissortail Wealth Management LLC owned about 0.18% of Nutex Health worth $308,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Bank of America Corp DE raised its holdings in Nutex Health by 6,590.3% in the 4th quarter. Bank of America Corp DE now owns 2,074 shares of the company's stock worth $66,000 after acquiring an additional 2,043 shares during the period. Northern Trust Corp bought a new position in Nutex Health in the 4th quarter worth approximately $200,000. Baader Bank Aktiengesellschaft bought a new stake in shares of Nutex Health in the fourth quarter valued at approximately $206,000. Millennium Management LLC bought a new position in Nutex Health during the fourth quarter worth $213,000. Finally, World Investment Advisors acquired a new position in Nutex Health during the 4th quarter valued at $217,000. Institutional investors and hedge funds own 5.32% of the company's stock.
Insider Buying and Selling at Nutex Health
In other news, CFO Jon Christian Bates bought 1,000 shares of the stock in a transaction dated Tuesday, April 8th. The shares were acquired at an average price of $81.81 per share, with a total value of $81,810.00. Following the acquisition, the chief financial officer now owns 4,888 shares in the company, valued at $399,887.28. This trade represents a 25.72% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 38.52% of the company's stock.
Analyst Ratings Changes
NUTX has been the subject of several research reports. Benchmark increased their target price on shares of Nutex Health from $150.00 to $300.00 and gave the company a "buy" rating in a research note on Thursday. Maxim Group boosted their price objective on Nutex Health from $75.00 to $100.00 and gave the company a "buy" rating in a research report on Tuesday, April 8th.
Get Our Latest Stock Analysis on Nutex Health
Nutex Health Stock Performance
NASDAQ:NUTX opened at $174.71 on Friday. The firm has a market capitalization of $965.80 million, a PE ratio of -18.61 and a beta of -0.10. The company has a quick ratio of 1.74, a current ratio of 1.77 and a debt-to-equity ratio of 3.36. Nutex Health Inc. has a 12-month low of $4.16 and a 12-month high of $182.00. The firm has a 50-day moving average price of $101.77 and a 200 day moving average price of $61.17.
Nutex Health (NASDAQ:NUTX - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported $2.56 EPS for the quarter, topping the consensus estimate of ($0.15) by $2.71. Nutex Health had a negative return on equity of 51.27% and a negative net margin of 14.09%. The business had revenue of $211.79 million during the quarter, compared to the consensus estimate of $81.09 million.
About Nutex Health
(
Free Report)
Nutex Health Inc operates as a physician-led, healthcare services, and operations company. It operates through three segments: Hospital, Population Health Management (PHM), and Real Estate. The PHM segment establishes and operates independent physician associations; and offers a cloud-based platform for healthcare organizations to provide value-based care and population health management.
Further Reading
Want to see what other hedge funds are holding NUTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nutex Health Inc. (NASDAQ:NUTX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Nutex Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nutex Health wasn't on the list.
While Nutex Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
